Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation.
Adult
Aged
Anti-Bacterial Agents
/ therapeutic use
Antibiotic Prophylaxis
Cefazolin
/ therapeutic use
Enterobacteriaceae
/ enzymology
Enterobacteriaceae Infections
/ microbiology
Ertapenem
/ therapeutic use
Female
Humans
Male
Middle Aged
Postoperative Complications
/ prevention & control
Prospective Studies
Retrospective Studies
beta-Lactam Resistance
Infection
Kidney transplantation
Multidrug-resistant bacteria
Surgical prophylaxis
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
22 07 2019
22 07 2019
Historique:
received:
15
03
2019
accepted:
09
07
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
24
11
2020
Statut:
epublish
Résumé
In recent years we have witnessed an increase in infections due to multidrug-resistant organisms in kidney transplant recipients (KTR). In our setting, we have observed a dramatic increase in infections caused by extended-spectrum betalactamase-producing (ESBL) Enterobacteriaceae in KTR. In 2014 we changed surgical prophylaxis from Cefazolin 2 g to Ertapenem 1 g. We compared bacterial infections and their resistance phenotype during the first post-transplant month with an historical cohort collected during 2013 that had received Cefazolin. During the study period 110 patients received prophylaxis with Cefazolin and 113 with Ertapenem. In the Ertapenem cohort we observed a non-statistically significant decrease in the percentage of early bacterial infection from 57 to 47%, with urine being the most frequent source in both. The frequency of infections caused by Enterobacteriaceae spp. decreased from 64% in the Cefazolin cohort to 36% in the Ertapenem cohort (p = 0.005). In addition, percentage of ESBL-producing strains decreased from 21 to 8% of all Enterobacteriaceae isolated (p = 0.015). After adjusted in multivariate Cox regression analysis, male sex (HR 0.16, 95%CI: 0.03-0.75), cefazolin prophylaxis (HR 4.7, 95% CI: 1.1-22.6) and acute rejection (HR 14.5, 95% CI: 1.3-162) were associated to ESBL- producing Enterobacteriaceae infection. Perioperative antimicrobial prophylaxis with a single dose of Ertapenem in kidney transplant recipients reduced the incidence of early infections due to ESBL-producing Enterobacteriaceae without increasing the incidence of other multidrug-resistant microorganisms or C. difficile.
Identifiants
pubmed: 31331289
doi: 10.1186/s12882-019-1461-4
pii: 10.1186/s12882-019-1461-4
pmc: PMC6647261
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ertapenem
G32F6EID2H
Cefazolin
IHS69L0Y4T
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
274Références
J Antimicrob Chemother. 2003 Sep;52(3):331-44
pubmed: 12917243
Liver Transpl. 2004 Jul;10(7):817-27
pubmed: 15237363
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Crit Care Med. 2007 Jan;35(1):89-95
pubmed: 17110877
N Engl J Med. 2006 Dec 21;355(25):2640-51
pubmed: 17182989
J Biol Chem. 2007 Oct 19;282(42):30414-22
pubmed: 17646161
Transplant Proc. 2007 Sep;39(7):2222-4
pubmed: 17889144
Nat Clin Pract Nephrol. 2008 May;4(5):252-64
pubmed: 18334970
Am J Transplant. 2008 May;8(5):1000-5
pubmed: 18727176
Transplant Proc. 2009 Jul-Aug;41(6):2262-4
pubmed: 19715892
Clin Infect Dis. 2010 Mar 1;50(5):625-63
pubmed: 20175247
J Clin Microbiol. 2010 May;48(5):1726-31
pubmed: 20181897
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
Crit Care. 2011;15(1):R55
pubmed: 21306623
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Clin Transplant. 2012 May-Jun;26(3):437-42
pubmed: 22004051
Antimicrob Agents Chemother. 2012 Jun;56(6):3409-12
pubmed: 22450984
Emerg Infect Dis. 2012 Jun;18(6):908-16
pubmed: 22607885
Transplant Proc. 2012 Dec;44(10):3029-32
pubmed: 23195020
Braz J Infect Dis. 2013 Mar-Apr;17(2):254-5
pubmed: 23453411
Surg Infect (Larchmt). 2013 Feb;14(1):73-156
pubmed: 23461695
Antimicrob Agents Chemother. 2013 Sep;57(9):4512-7
pubmed: 23836184
Transplantation. 2013 Nov 15;96(9):843-9
pubmed: 23883973
Ann Surg Oncol. 2014 Feb;21(2):513-9
pubmed: 24114052
Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55
pubmed: 24329732
Transpl Infect Dis. 2014 Apr;16(2):171-87
pubmed: 24661423
Clin Microbiol Infect. 2014 Sep;20 Suppl 7:49-73
pubmed: 24861521
J Antimicrob Chemother. 2014 Dec;69(12):3379-86
pubmed: 25151205
Surgery. 2015 Jan;157(1):104-10
pubmed: 25304836
J Antimicrob Chemother. 2015 Mar;70(3):914-21
pubmed: 25480492
Am J Transplant. 2015 Apr;15(4):1021-7
pubmed: 25676738
Crit Care. 2015 May 04;19:218
pubmed: 25936721
Clin Microbiol Infect. 2015 Dec;21(12):1104.e1-8
pubmed: 26235196
PLoS One. 2015 Aug 03;10(8):e0134737
pubmed: 26237422
Virulence. 2016 Apr 2;7(3):329-40
pubmed: 26766415
BMC Nephrol. 2017 May 19;18(1):164
pubmed: 28525997
Clin Transplant. 2019 Feb 21;:e13507
pubmed: 30793386
Am J Infect Control. 1996 Oct;24(5):380-8
pubmed: 8902113
Nephrol Dial Transplant. 1998 Jul;13(7):1637-41
pubmed: 9681704